Search

Introduction: In response to growing concerns over negative emotions towards climate change worldwide, it is essential that a validated and reliable scale is available for the generalizability of the constructs being measured, and it is not just applicable to Western context, but also the East. Method: The present study aims to conduct a psychometric investigation of the 13-item Climate Change Anxiety Scale (CCAS) of Clayton and Karazsia in Traditional Chinese using a large sample (N = 1,567) of Chinese individuals in Hong Kong, China. The CCAS was translated, back-translated, cross-culturally adapted and pilot-tested. We performed descriptive, scale reliability, exploratory factor and confirmatory factor analyses. Results: Unlike the two-factor structure of the original scale, our results revealed a three-factor structure of the 13-item CCAS version that captured three dimensions of climate change anxiety: intrusive symptoms, reflections on climate anxiety, and functional impairment. The scale showed good goodness-of-fit indices, internal consistency and reliability. The Chinese CCAS version demonstrated high levels of reliability estimates and significant, albeit weak, correlations with the relevant constructs of well-being, anxiety and depression, environmental orientation, self-efficacy and belief denial. Conclusion: Overall, the Chinese CCAS version has good reliability and validity, and it can be used as a valid assessment tool for climate change anxiety screening with Chinese individuals, thus providing a foundation for better understanding various climate change–related emotions through an anxiety lens in the Chinese context.

NXY-059 is a novel free radical-trapping neuroprotectant that reduces infarct size and preserves brain function in animal models of acute ischemic stroke. It is the first neuroprotectant to demonstrate a reduction in global disability in a phase III clinical trial, as measured by the modified Rankin Scale. Any effect of NXY-059 on hemostasis may be important when treating stroke patients. This phase I randomized, double-blind, placebo-controlled, 3- period crossover study compared the effect of NXY-059, desmopressin, and placebo on bleeding time, platelet aggregation, and adhesion in 30 healthy volunteers. NXY- 059 did not prolong bleeding time compared with placebo: mean (SD) time for NXY-059, 369.5 seconds (125.0 seconds) versus placebo, 369.1 seconds (136.0 seconds). There were no significant effects on platelet aggregation or adhesion. At a mean unbound plasma concentration (Cuss) of 335 μmol/L, NXY-059 was well tolerated, with no major safety concerns identified. In conclusion, NXY-059 does not appear to affect primary hemostasis. [ABSTRACT FROM AUTHOR]